Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab

Rei Kamitani, Toshiyuki Ando, Kazuya Hanai, Arihito Tanaka, Fumihiro Kashizaki, Yasutomo Sekido, Ryuichi Mizuno

研究成果: Article査読

抄録

Background: Small cell bladder carcinoma (SCBC) is a rare and aggressive malignant tumor with no established treatment guidelines. Its treatment algorithm has been based on the small cell lung cancer (SCLC) guidelines. Metastatic SCBC has poor prognosis (even when treated with platinum-based chemotherapy, which is usually used for extensive-disease SCLC). Case presentation: Herein, we report a case of a 71-year-old man with SCBC who underwent radical cystectomy and received adjuvant chemotherapy with gemcitabine and cisplatin. However, recurrent tumors were found 6 months postoperatively. The patient was then treated with carboplatin, etoposide, and atezolizumab and achieved complete response. He continues receiving maintenance therapy with atezolizumab monotherapy without any evidence of recurrence over the 12 months follow up. Conclusion: To our knowledge, this is the first case of metastatic SCBC where carboplatin, etoposide, and atezolizumab achieved long-term complete response.

本文言語English
論文番号170
ジャーナルBMC Urology
22
1
DOI
出版ステータスPublished - 2022 12月

ASJC Scopus subject areas

  • 生殖医学
  • 泌尿器学

フィンガープリント

「Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル